Phase 2 N=31 Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
Advanced Melanoma · Unresectable Melanoma
Primary: Overall Response Rate (ORR) — 10 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Phase 3 N=676 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Melanoma · Metastases
Primary: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone — 9.95…
Phase 2 N=4 Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Melanoma · Skin Cancer
Primary: Complete Response Rates for Patients With Metastatic Melanoma — 0; 0; 0; 0 Participants
Phase 2 N=3 Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Melanoma
Primary: Phase I, Number of Participants With SAE and DLT — 0; 0; 1; 0 Participants
Phase 2 N=15 Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Metastatic Melanoma
Primary: Immune Response Rate — 0.29; 0.67 proportion of participants
Phase 2 N=16 Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
Metastatic Melanoma · Stage IIIB Cutaneous Melanoma AJCC v7 · Stage IIIC Cutaneous Melanoma AJCC v7
Primary: Overall Response Rate in Each Arm — 1; 1; 2; 1 Participants
Phase 2 N=4 Radiation and Combination Immunotherapy for Melanoma
Metastatic Melanoma
Primary: Objective Response Rate (ORR) — 1; 1 Participants
Phase 2 N=64 Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8 · Pathologic Stage III Cutaneous Melanoma AJCC v8 · Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Primary: Pathologic Complete Response Rate (pCR) — 66.7; 13.3; 38.2 percentage of participants
Phase 2 N=24 Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
Melanoma · Skin Cancer
Primary: Clinical Tumor Regression. — 0; 0; 6; 0 Participants
Phase 2 N=52 Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
Melanoma
Primary: Response to Neoadjuvant Therapy by Therapy Arms: Clinical Response Rates (CR + PR + SD) — 4; 7; 14; 11 Participants
Phase 2 N=64 Ipilimumab + Temozolomide in Metastatic Melanoma
Metastatic Melanoma
Primary: 6-Month Progression-Free Survival (PFS) Rate — 29 participants
Phase 2 N=6 MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Melanoma
Primary: Number of Participants With Dose Limiting Toxicities (DLT) [Phase I] — 1 Participants
Phase 2 N=1,009 A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Melanoma
Primary: the Incidence of Highgrade (CTCAE v4.0 Grade 3 or Higher), Treatment Related,Select Adverse Events. — 16; 0; 30; 0 Number of Participants
Phase 2 N=17 Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
Melanoma
Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants
Phase 2 N=10 Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Unresectable Malignant Neoplasm · Melanoma · Metastatic Melanoma
Primary: Resectability Rate — 8; 2 Participants
Phase 2 N=7 CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
Metastatic Melanoma · Stage IV Cutaneous Melanoma AJCC v6 and v7
Primary: CTL With Anti-CTLA4
Phase 2 N=49 Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
Melanoma (Skin)
Primary: 9-week Progression-free Survival Rate — 0.44 proportion of patients
Phase 2 N=14 Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
Metastatic Melanoma
Primary: Response Rate: The Number of Participants Who Completed the Maximum Time Allowed on Study Without Being Affected by Tumor Recurrence or Progression. — 0 Participants
Phase 2 N=10 Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
Skin Cancer · Metastatic Melanoma
Primary: Response — 0; 0; 8; 2 Participants
Phase 1 N=155 Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
Malignant Melanoma
Primary: Investigator-Assessed Objective Response Rate (ORR) — 12.0; 36.4; 38.5 Percentage of Participants
Phase 2 N=95 Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
Melanoma (Skin)
Primary: Progression-free Survival at 6 Months — 32.8; 56.1 % of patients alive and progression free
Phase 2 N=32 Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
Melanoma · Skin Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 18.8 Percentage of participants
Phase 2 N=76 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Intraocular Melanoma · Melanoma (Skin)
Primary: Percentage of Participants With Immune-related Adverse Events (irAEs) — 80.0; 72.0; 65.4 Percentage of participants
Phase 2 N=39 Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate, Defined Per RECIST 1.1 — 1; 5; 11; 16 Participants
Phase 2 N=5 LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Melanoma
Primary: Dose Limiting Toxicity (DLT) [Phase I] — 1 Participants
Phase 2 N=10 Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
Metastatic Melanoma · Stage III Cutaneous Melanoma AJCC v7 · Stage IV Cutaneous Melanoma AJCC v6 and v7
Primary: Number of Participants With Immune-Related Response — 8 Participants
Phase 2 N=24 Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Metastatic Melanoma · Mucosal Melanoma · Stage IV Cutaneous Melanoma AJCC v6 and v7
Primary: Progression-free Survival (PFS) — 139; 94 days
Phase 2 N=44 High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
Melanoma
Primary: Objective Response Rate — 25 percentage of participants
Phase 3 N=502 Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
Melanoma
Primary: Overall Survival (OS) — 11.17; 9.07 Months — p=0.0009